We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Alliance for Infectious Disease Treatments

By Biotechdaily staff writers
Posted on 29 May 2002
A collaboration to develop new antibody products to treat infectious diseases has been announced by two Danish companies: Genmab A/S (Copenhagen; www.genmab.com) and Ace BioSciences (Odense; www.acebiosciences). More...
Under their agreement, the companies will share development costs and revenues.

The alliance will combine Ace BioSciences's expertise in finding novel infectious disease targets with Genmab's broad antibody development capabilities and preclinical tools to generate and characterize fully human antibodies. Ace BioSciences will provide commercially promising targets, while Genmab will use its antibody technology to create and develop new therapeutics. Genmab creates and develops fully human antibodies for the treatment of disease. Ace BioSciences's focus on infectious diseases is based on a broad biotechnology platform that integrates biology and analytical chemistry. The company's protein interaction technology is used to discover protein targets in a wide range of infectious bacteria and fungi.

"We are very excited by this alliance with Genmab because the company's expertise and proven track record in developing therapeutic antibodies positions Ace BioSciences on a fast track to develop treatments for infectious diseases,” said Ejvind Mortz, Ph.D., CEO of Ace BioSciences.




Related Links:
Genmab
Ace BioSciences

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.